Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC grew its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 11.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 141,622 shares of the biotechnology company’s stock after acquiring an additional 14,668 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.22% of Blueprint Medicines worth $13,100,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of BPMC. Swiss National Bank grew its holdings in Blueprint Medicines by 1.6% in the third quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company’s stock valued at $10,748,000 after purchasing an additional 1,800 shares during the period. S&CO Inc. boosted its holdings in shares of Blueprint Medicines by 49.3% in the 3rd quarter. S&CO Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $925,000 after purchasing an additional 3,300 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $999,000. Covestor Ltd increased its holdings in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after buying an additional 403 shares during the last quarter. Finally, M&G PLC purchased a new position in shares of Blueprint Medicines in the 3rd quarter worth $9,101,000.

Blueprint Medicines Trading Up 0.2 %

NASDAQ:BPMC opened at $94.81 on Thursday. The firm has a market capitalization of $6.02 billion, a price-to-earnings ratio of -44.93 and a beta of 0.59. The business’s 50-day moving average price is $90.00 and its two-hundred day moving average price is $98.70. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. Blueprint Medicines Co. has a 1-year low of $64.79 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the company earned ($2.20) earnings per share. The company’s revenue for the quarter was up 126.5% compared to the same quarter last year. On average, equities analysts expect that Blueprint Medicines Co. will post -3.61 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BPMC. Barclays lifted their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. Needham & Company LLC reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Robert W. Baird increased their price target on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and a consensus target price of $122.11.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the sale, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.